Moreover, research on inhibitors targeting FTO and ALKBH5 is advancing, with diverse inhibitors identified through high-throughput screening and structural optimization, demonstrating significance in targeting tumors, obesity, and other diseases. Here, ALKBH5 is linked to obesity due to melanocortin 4 receptor deficiency.